Capital Fund Management (CFM)
BNGO icon

Capital Fund Management (CFM)’s Bionano Genomics BNGO Stock Holding History

Capital Fund Management (CFM)’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-144
Closed -$475K – 1597
2021
Q3 		$475K Buy
+144
New +$504K ﹤0.01% 1387

Other funds holding BNGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Capital Fund Management (CFM)'s BNGO Position: Q3 2021 in Review

Capital Fund Management (CFM) sold out of Bionano Genomics (BNGO) in Q3 2021, closing a stake of 310 shares — an estimated $1.08M sold.

Capital Fund Management (CFM) first reported a position in BNGO in Q2 2021 and held it in 1 quarter. The position peaked at $1.36M in Q2 2021. 147 funds tracked by Wall St. Rank hold BNGO as of Q3 2021.

  • Capital Fund Management (CFM) reported no remaining Bionano Genomics position as of Q3 2021 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 310 Bionano Genomics shares in Q3 2021, an estimated $1.08M.
  • Capital Fund Management (CFM) first reported a position in Bionano Genomics in Q2 2021 and held it in 1 quarter.
  • Capital Fund Management (CFM)'s Bionano Genomics position peaked at $1.36M in Q2 2021.
  • 147 funds tracked by Wall St. Rank held Bionano Genomics as of Q3 2021.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2021, filed 12 Nov 2021.